Sartorius AG · XETR:SRT
Sartorius — Investor Presentation (February 2020)
24 slides from Sartorius's investor presentation, February 2020
Slide 1: Simplifying Progress: This is Sartorius
Simplifying Progress This is Sartorius Company Presentation | February 2020
Slide 2: Partner of biopharmaceutical research and industry
Partner of biopharmaceutical research and industry We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine. 2 This is Sartorius
Slide 3: Pioneers for around 150 years
Pioneers for around 150 years 1870 At his precision machine workshop, 24-year-old Florenz Sartorius developed the short-beam analytical balance. Evolving from a “university mechanician” into a leading 1927 A “joint venture” with Nobel Prize laureate Richard life science group Zsigmondy expanded the
Slide 4: Sartorius in brief
Sartorius in brief 60+ Locations worldwide, headquartered in Göttingen, Germany 9,016 Employees ~1.83bn Sales revenue 27.1% EBITDA margin1 ~€12.5bn ~35% ~40% ~25% Sartorius AG market capitalization; Sales revenue Sales revenue Sales revenue included in MDAX and TecDax Americas EMEA Asia | Pacific As
Slide 5: Strong company values as the basis of all our activities
Strong company values as the basis of all our activities Sustainability Openness Enjoyment Growing profitably and acting Driving change and progress Working in an energetic and responsibly towards all stakeholders internally and externally rewarding environment 5 This is Sartorius
Slide 6: Strategic focus on the biopharma market
Strategic focus on the biopharma market Bioprocess Solutions Division Molecule Cell line and Upstream & development process development downstream production Quality control & testing Lab Products & Services Division 6 This is Sartorius
Slide 7: Attractive market environment with strong growth opportunities
Attractive market environment with strong growth opportunities Favorable 9bn people by 2050; demographics >2bn 60 yrs or older Rise of ~30% CAGR for biosimilar ~8% biosimilars sales 2018–2022 CAGR for biopharma market 2018–2025 Strong R&D pipeline; advances in gene and >40% share of biologics in cel
Slide 8: Biopharmaceuticals
What are biopharmaceuticals? Active Agent Manufacturing Administration Advantages First-time or improved Chemical drugs treatment of serious illnesses, such as cancer, multiple sclerosis, rheumatism Small molecules Chemical synthesis Mainly oral Targets only diseased cells; fewer side effects Bi
Slide 9: Only one out of 10,000 new drug candidates reaches the market
Only one out of 10,000 new drug candidates reaches the market Drug discovery Testing & Clinical trials Drug approval improving 4 ½ years 1 year 5 ½ years 1 ½ years €110m €640m €60m >10 years 1 in 10,000 From drug discovery Chance for a candidate to approval ~€500m to make it to the market Average co
Slide 10: The manufacture of biopharmaceuticals is complex
The manufacture of biopharmaceuticals is complex 10 This is Sartorius
Slide 11: The consequence: Biotech medications are extremely expensive
The consequence: Biotech medications are extremely expensive HUMIRA® ZOLGENSMA® Annual revenue of $18 billion; is used to treat rheumatism Currently the world‘s most expensive medical drug; and other inflammatory autoimmune diseases, such as gene therapie used to treat spinal muscular atrophy Crohn’
Slide 12: Our ambition: Reduce costly trial & error in drug discovery
Our ambition: Reduce costly trial & error in drug discovery Our laboratory tools support researchers ... ... in understanding diseases ... in conducting experiments and evaluating their data ... in identifying the right molecules and developing new medicine 12 This is Sartorius
Slide 13: Our solution: Tools and instruments to accelerate drug development
Our solution: Tools and instruments to accelerate drug development Products Premium laboratory instruments, filtration & consumables and innovative bioanalytical systems Live-cell analysis High-throughput Balances Pipettes Application areas screening Life science research Quality control & testi
Slide 14: Our goal: Simplify manufacturing of biopharmaceuticals
Our goal: Simplify manufacturing of biopharmaceuticals Our technologies empower engineers in the biopharma industry to ... ... set up robust, flexible and safe processes for industrial production ... reduce set-up costs ... enhance the product yield 14 This is Sartorius
Slide 15: Our solution: Innovative technologies for all phases drug production
Our solution: Innovative technologies for all phases drug production Products Scalable single-use technologies for the production of biopharmaceuticals and digital tools for biopharma data analytics Filtration Cell culture technology & media Application areas Biopharmaceutical manufacturing Qual
Slide 16: The widest offering of solutions in the industry
The widest offering of solutions in the industry Upstream Production of the desired drug Culture media Seed cultivation Scale-up Production preparation Downstream Isolation & filling of the desired drug Final Cryo- Sterile Concentration Virus removal Polishing Viral Clarification and filling preserv
Slide 17: Single-use production systems are becoming increasingly prevalent
Single-use production systems are becoming increasingly prevalent Stainless Steel Single-Use High initial investment outlay Faster setup and lower investment High cleaning effort and expense throughout the entire life cycle Risk of contamination Lower consumption of water and energy Reduced risk of
Slide 18: Data analytics has huge potential for the biopharmaceutical industry
Data analytics has huge potential for the biopharmaceutical industry Sartorius supports its customers in the digitalization and automation of their Data aggregation processes with its leading software for analysis of bioprocess data. Enhanced process control and robustness Improved product quali
Slide 19: Leading market positions worldwide in both segments
Leading market positions worldwide in both segments Fluid mgmt. Fermentation Filtration Lab balances Microb. analysis Lab filtration Pipettes #1 #1 #3 #2 #2 #3 #4 19 This is Sartorius
Slide 20: Acquisitions strengthen and differentiate the Sartorius portfolio
Acquisitions strengthen and differentiate the Sartorius portfolio Essen Intellicyt ViroCyt BioScience Acquisitions to remain part of strategy 2013 2014 2015 2016 2017 2018 2019 2020 TAP AllPure Bio Cellca kSep Umetrics Biological Biosystems Technologies Outsource Industries 20 This is Sartorius
Slide 21: Sales revenue has more than doubled over the last 5 years
Sales revenue has more than doubled over the last 5 years +14.8% Sales CAGR +13.8% +13.2% 40 1900 ~€1.83bn EBITDA-margin1 +7.4pp +9.3% 38 +18.2% 1700 36 +16.0% 34 1500 32 1300 +12.6% 30 1100 +8.8% 28 +13.6% ~€891m 900 27,1 26 25,1 25.9 700 €733m 25.0 24 23.6 ~€650m 22 500 21.0 20 19.7 20.1 20.5 300
Slide 22: Sartorius 2025 targets and initiatives
Sartorius 2025 targets and initiatives Strategic initiatives 2025 targets Regional Participate in strong Chinese market growth ~ €4bn Continue to outperform the important U.S. market Sales revenue Portfolio Add high-impact innovations, e.g. digital tools ~2/3 ~1/3 Enhance process development
Slide 23: Recent investments: Infrastructure prepared for further growth
Recent investments: Infrastructure prepared for further growth Göttingen, Germany Aubagne, France Expansion of lab instrument Capacity extension for manufacture and extension of single-use bag capacities for filter production; production new Application Center Beijing & Shanghai, China Boston, USA P
Slide 24: Thank you.
Thank you.